PBAC's latest decision on Polatuzumab vedotin: Noted (2025). Considered for Treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) in patients with an International Prognostic Index (IPI) score of 3–5, administered in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola+R-CHP).
PBAC outcome
Noted
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
3
first 2019
Submissions
3
2019 → 2025
Eligible population
Adults with previously untreated DLBCL with an International Prognostic Index (IPI) score of 3–5 and WHO ECOG performance status ≤2.
Therapy area
Haematology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
PFS
Key trials
POLARIX
Comparator
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
Economic model
CUA
ICER note
ICER values are redacted in the public summary document; specific numeric ICERs are not published.
Risk sharing
Risk-sharing arrangement in place — A risk share agreement was proposed with a rebate above proposed utilisation estimates, which assumed a 19% increase in utilisation compared to the November 2022 pre-PBAC response.
Submission history
Nov 2019: Recommended with restriction · Authority Required
Nov 2022: Recommended with restriction · Authority Required